Search
forLearn
5 / 801 resultslearn PTD-DBM
learn Dextran
learn Trichogen
learn multipeptides
Research
5 / 1000+ results
research Cellular Plasticity in Cutaneous Wound Healing
Cells can change to help heal wounds better.
research Epidermal stem cells: an update on their potential in regenerative medicine
Epidermal stem cells have potential for personalized regenerative medicine but need careful handling to avoid cancer.
research ROBERTSONIAN TRANSLOCATION PATIENT WITH RECURRENT MISCARRIAGE
Robertsonian translocation can cause recurrent miscarriages.
research P-055 MONOZYGOTIC TRANSGENDER MALE TWINS: A CASE REPORT HIGHLIGHTING GENETIC CONCORDANCE IN GENDER DYSPHORIA
Genetics may play a significant role in gender dysphoria.
research Alterations in the expression of specific epidermal keratin markers in the hairless mouse by the topical application of the tumor promoters 2,3,7,8-tetrachlorodibenzo-p-dioxin and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate
TCDD changes skin cell growth and keratin production in mice.
Community Join
5 / 1000+ resultscommunity Comparing the effect of T suppression and DHT suppression
Trans women discuss using finasteride and dutasteride for hair loss and whether to continue after testosterone suppression. One user reduced dutasteride dosage after achieving undetectable testosterone levels.
community Comparing the effect of T suppression and DHT suppression
The conversation discusses the use of 5-alpha-reductase inhibitors like finasteride and dutasteride for hair loss in transgender women, particularly in relation to testosterone suppression. The original poster has been using dutasteride and is considering stopping it due to undetectable testosterone levels.
community I don’t understand this, is he equating taking Fin with being on HRT?
The conversation is about using finasteride and testosterone replacement therapy (TRT) for hair loss and their role in gender-affirming care. It debates whether these treatments are considered hormone replacement therapy (HRT) and their implications for both cisgender and transgender individuals.
community Trial for TDM-105795 update from research office
The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.